Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Zhan, Shipeng; Tang, Min; Liu, Fang; Xia, Peiyuan; Shu, Maoqin; Wu, Xiaojiao

doi:10.1002/14651858.cd012502.pub2

Cited by 109Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismBlood Pressure and Hypertension Studies

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Open access

Zhan, Shipeng, Tang, Min, Liu, Fang, Xia, Peiyuan, Shu, Maoqin, Wu, Xiaojiao·2018·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd012502.pub2PMC PMC6516816

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Cardiovascular disease (CVD) remains an important cause of mortality and morbidity, and high levels of blood cholesterol are thought to be the major modifiable risk factors for CVD. The use of statins is the preferred treatment strategy for the prevention of CVD, but some people at high-risk for CVD are intolerant to statin therapy or unable to achieve their treatment goals with the maximal recommended doses of statin. Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events remains uncertain. Results from clinical studies are inconsistent and a thorough evaluation of its efficacy and safety for the prevention of CVD and mortality is necessary. OBJECTIVES: To assess the efficacy and safety of ezetimibe for the prevention of CVD and all-cause mortality. SEARCH METHODS: We searched the CENTRAL, MEDLINE, Embase and Web of Science on 27 June 2018, and two clinical trial registry platforms on 11 July 2018. We checked reference lists from primary studies and review articles for additional studies. No language restrictions were applied. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared ezetimibe versus placebo or ezetimibe plus other lipid-modifying drugs versus other lipid-modifying drugs alone in adults, with or without CVD, and which had a follow-up of at least 12 months. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, extracted data, assessed risk of bias and contacted trialists to obtain missing data. We performed statistical analyses according to the Cochrane Handbook for Systematic Reviews of Interventions and used the GRADE to assess the quality of evidence. MAIN RESULTS: We included 26 RCTs randomising 23,499 participants. All included studies assessed effects of ezetimibe plus other lipid-modifying drugs compared with other lipid-modifying drugs alone or plus placebo. Our findings were driven by the largest study (IMPROVE-IT), which had weights ranging from 41.5% to 98.4% in the different meta-analyses.Ezetimibe with statins probably reduces the risk of major adverse cardiovascular events compared with statins alone (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.90 to 0.98; a decrease from 284/1000 to 267/1000, 95% CI 256 to 278; 21,727 participants; 10 studies; moderate-quality evidence). Trials reporting all-cause mortality used ezetimibe with statin or fenofibrate and found they have little or no effect on this outcome (RR 0.98, 95% CI 0.91 to 1.05; 21,222 participants; 8 studies; high-quality evidence). Adding ezetimibe to statins probably reduces the risk of non-fatal myocardial infarction (MI) (RR 0.88, 95% CI 0.81 to 0.95; a decrease from 105/1000 to 92/1000, 95% CI 85 to 100; 21,145 participants; 6 studies; moderate-quality evidence) and non-fatal stroke (RR 0.83, 95% CI 0.71 to 0.97; a decrease 32/1000 to 27/1000, 95% CI 23 to 31; 21,205 participants; 6 studies; moderate-quality evidence). Trials reporting cardiovascular mortality added ezetimibe to statin or fenofibrate, probably having little or no effect on this outcome (RR 1.00, 95% CI 0.89 to 1.12; 19457 participants; 6 studies; moderate-quality evidence). The need for coronary revascularisation might be reduced by adding ezetimibe to statin (RR 0.94, 95% CI 0.89 to 0.99; a decrease from 196/1000 to 184/1000, 95% 175 to 194; 21,323 participants; 7 studies); however, no difference in coronary revascularisation rate was observed when a sensitivity analysis was limited to studies with a low risk of bias.In terms of safety, adding ezetimibe to statins may make little or no difference in the risk of hepatopathy (RR 1.14, 95% CI 0.96 to 1.35; 20,687 participants; 4 studies; low-quality evidence). It is uncertain whether ezetimibe increase or decrease the risk of myopathy (RR 1.31, 95% CI 0.72 to 2.38; 20,581 participants; 3 studies; very low-quality evidence) and rhabdomyolysis, given the wide CIs and low event rate. Little or no difference in the risk of cancer, gallbladder-related disease and discontinuation due to adverse events were observed between treatment groups. For serum lipids, adding ezetimibe to statin or fenofibrate might further reduce the low-density lipoprotein cholesterol (LDL-C), total cholesterol and triglyceride levels and likely increase the high-density lipoprotein cholesterol levels; however, substantial heterogeneity was detected in most analyses.None of the included studies reported on health-related quality of life. AUTHORS' CONCLUSIONS: Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk o

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012502.pub2

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Ezetimibe's safety and efficacy has been confirmed in multiple meta-analyses.
“Ezetimibe’s safety and efficacy has been confirmed in multiple meta-analyses [61, 66–70].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [70]
The Authors’ conclusions report modest cardiovascular benefits, chiefly fewer non-fatal heart attacks and strokes, and the discussion says four other reviews found largely consistent results. But the same conclusions say evidence is insufficient to determine whether ezetimibe increases adverse-event risks; this source does not confirm its safety. (LLM, conf=0.91)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · see citing works
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · see citing works
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782 · see citing works
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596 · see citing works
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596 · see citing works
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Assessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256 · see citing works
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,840 · see citing works
Untitled work
(2008) · Cited by 3,790 · see citing works
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782 · see citing works
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479 · see citing works
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331 · see citing works
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,781 · see citing works
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644 · see citing works
Cardiovascular disease in Europe: epidemiological update
Nichols, M. S., Townsend, N. P., Scarborough, P., & Rayner, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht356 · Cited by 1,349 · see citing works
Cardiovascular disease in Europe 2014: epidemiological update
Nichols, M. S., Townsend, N. P., Scarborough, P., & Rayner, M. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu299 · Cited by 1,294 · see citing works
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241 · see citing works
Demographic and epidemiologic drivers of global cardiovascular mortality
Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406656 · Cited by 1,188 · see citing works
Chapter 10: Addressing reporting biases
Egger, M., & Moher, D. (2011) · Cited by 977 · see citing works
Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013
Roth, G. A., Huffman, M. D., Moran, A. E., Feigin, V. L., Mensah, G. A., Naghavi, M., & Murray, C. J. L. (2015) · Circulation · doi:10.1161/circulationaha.114.008720 · Cited by 883 · see citing works
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784 · see citing works
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 772 · see citing works
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720 · see citing works
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682 · see citing works
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 643 · see citing works
Ezetimibe
Kosoglou, T., Statkevich, P., Johnson‐Levonas, A. O., Paolini, J. F., Bergman, A. J., & Alton, K. B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00002 · Cited by 474 · see citing works
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Oka, H., Nakao, K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.065 · Cited by 459 · see citing works
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., Park, J.-G., White, J. A., Bohula, E. A., & Braunwald, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030950 · Cited by 427 · see citing works
Anti-PCSK9 Monotherapy for Hypercholesterolemia
Koren, M. J., Lundqvist, P., Bolognese, M., Neutel, J. M., Monsalvo, M. L., Yang, J., Kim, J. B., Scott, R., Wasserman, S. M., & Bays, H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.018 · Cited by 411 · see citing works
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Cannon, C. P., Cariou, B., Blom, D. J., McKenney, J. M., Lorenzato, C., Pordy, R. C., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 401 · see citing works
Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport
Jia, L., Betters, J. L., & Yu, L. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142233 · Cited by 384 · see citing works
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 349 · see citing works
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340 · see citing works
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 328 · see citing works
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., Alton, K. B., Sybertz, E. J., & Davis, H. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703235 · Cited by 325 · see citing works
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320 · see citing works
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
SHARP Collaborative Group (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.012 · Cited by 319 · see citing works
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 297 · see citing works
Ezetimibe therapy: mechanism of action and clinical update
Toth, P. P., Phan, B. A. P., & Dayspring, T. D. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 294 · see citing works
Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., & On behalf of the Guideline Development Group (2014) · BMJ · doi:10.1136/bmj.g4356 · Cited by 292 · see citing works
Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia
Vereckei, A., Duray, G. Z., Szénási, G., Altemose, G. T., & Miller, J. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl473 · Cited by 246 · see citing works
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
Fleg, J. L., Méte, M., Howard, B. V., Umans, J. G., Roman, M. J., Ratner, R. E., Silverman, A., Galloway, J. M., Henderson, J. A., Weir, M. R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.031 · Cited by 243 · see citing works
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 241 · see citing works
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · see citing works
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)
Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.017 · Cited by 223 · see citing works
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205 · see citing works
Atherothrombotic risk stratification and ezetimibe for secondary prevention
Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J.-G., Murphy, S. A., White, J. A., Kesaniemi, Y. A., Pedersen, T. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.070 · Cited by 204 · see citing works
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
Giugliano, R. P., Wiviott, S. D., Blazing, M. A., Ferrari, G. M. D., Park, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Cannon, C. P., & D, E. B. M. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0083 · Cited by 204 · see citing works
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 202 · see citing works
Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study
Rossebø, A. B., Pedersen, T. R., Allen, C., Boman, K., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, V. A. Y., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.064 · Cited by 147 · see citing works
Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Bohula, E. A., Wiviott, S. D., Giugliano, R. P., Blazing, M. A., Park, J.-G., Murphy, S. A., White, J. A., Mach, F., Van de Werf, F., Dalby, A. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029095 · Cited by 142 · see citing works
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx162 · Cited by 136 · see citing works
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
van der Graaf, A., Cuffie-Jackson, C., Vissers, M., Trip, M., Gagné, C., Shi, G., Veltri, E., Avis, H., & Kastelein, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.002 · Cited by 134 · see citing works
The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD
Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., Ball, S. T., Baxter, A., Blackwell, L. S., Cairns, H., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.11.018 · Cited by 107 · see citing works
Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia
McKenney, J. M., Farnier, M., Lo, K.-W., Bays, H. E., Perevozkaya, I., Carlson, G. L., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.072 · Cited by 106 · see citing works
Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins
Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.099 · Cited by 102 · see citing works
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., D, E. B. M., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 94 · see citing works
Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -
Kovárník, T., Mintz, G. S., Skalická, H., Král, A., Horák, J., Škulec, R., Uhrová, J., Pavel Martasek, E., Downe, R., Wahle, A., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0730 · Cited by 89 · see citing works
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia
Kastelein, J. J. P., Sager, P. T., de Groot, E., & Veltri, E. P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.06.024 · Cited by 88 · see citing works
An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
Califf, R. M., Lokhnygina, Y. V., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.004 · Cited by 88 · see citing works
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88 · see citing works
The Effect of Ezetimibe on Peripheral Arterial Atherosclerosis Depends Upon Statin Use at Baseline
West, A. M., Anderson, J. D., Meyer, C., Epstein, F., Wang, H., Hagspiel, K., Berr, S., Harthun, N., Dimaria, J. M., Hunter, J. R., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.005 · Cited by 87 · see citing works
The Vytorin on Carotid Intima‐Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney, A., Ceballos, G. M., Asbún, J., Solache, G., Mendoza, E., Vela, A., & Meaney, E. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337011 · Cited by 75 · see citing works
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Kato, E. T., Cannon, C. P., Blazing, M. A., Bohula, E. A., Güneri, S., White, J. A., Murphy, S. A., Park, J., D, E. B. M., & Giugliano, R. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006901 · Cited by 73 · see citing works
Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy
Gudzune, K. A., Monroe, A. K., Sharma, R., Ranasinghe, P. D., Chelladurai, Y., & Robinson, K. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2526 · Cited by 70 · see citing works
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
Sudhop, T., Reber, M., Tribble, D. L., Sapre, A., Taggart, W. V., Gibbons, P. H., Musliner, T., von Bergmann, K., & Lütjohann, D. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900004-jlr200 · Cited by 68 · see citing works
Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography
Auscher, S., Heinsen, L. J., Nieman, K., Vinther, K. H., Løgstrup, B. B., Møller, J. E., Broersen, A., Kitslaar, P. H., Lambrechtsen, J., & Egstrup, K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.007 · Cited by 67 · see citing works
Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe
Habara, M., Nasu, K., Terashima, M., Ko, E., Yokota, D., Ito, T., Kurita, T., Teramoto, T., Kimura, M., Kinoshita, Y., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.038 · Cited by 65 · see citing works
Long-term safety and, tolerability profiles andlipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study
Masana, L., Mata, P., Gagné, C., Sirah, W., Cho, M., Johnson‐Levonas, A. O., Meehan, A. G., Troxell, J. K., & Gumbiner, B. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.011 · Cited by 65 · see citing works
Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease
Masuda, J., Tanigawa, T., Yamada, T., Nishimura, Y., Sasou, T., Nakata, T., Sawai, T., Fujimoto, N., Dohi, K., Miyahara, M., et al. (2015) · International Heart Journal · doi:10.1536/ihj.14-311 · Cited by 60 · see citing works
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia
Ballantyne, C. M., Lipka, L., Sager, P. T., Strony, J. T., Alizadeh, J., Suresh, R., & Veltri, E. P. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00278.x · Cited by 51 · see citing works
Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial
Hougaard, M., Hansen, H. S., Thayssen, P., Antonsen, L., Junker, A., Veien, K. T., & Jensen, L. O. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.11.010 · Cited by 50 · see citing works
Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting
Takase, S., Matoba, T., Nakashiro, S., Mukai, Y., Inoue, S., Oi, K., Higo, T., Katsuki, S., Takemoto, M., Suematsu, N., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308388 · Cited by 49 · see citing works
A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin
Ran, D., Nie, H.-J., Gao, Y.-L., Deng, S., Du, J., Liu, Y., Jing, X., & She, Q. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.099 · Cited by 48 · see citing works
Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque ― The ZIPANGU Study ―
Ueda, Y., Hiro, T., Hirayama, A., Komatsu, S., Matsuoka, H., Takayama, T., Ishihara, M., Hayashi, T., Saito, S., Kodama, K., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0193 · Cited by 48 · see citing works
Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias
Wierzbicki, A. S., Doherty, E., Lumb, P. J., Chik, G., & Crook, M. A. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x28872 · Cited by 47 · see citing works
Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease
Wang, X., Zhao, X., Li, L., Yao, H.-M., Jiang, Y. J., & Zhang, J. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.10.012 · Cited by 47 · see citing works
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome
Hibi, K., Sonoda, S., Kawasaki, M., Otsuji, Y., Murohara, T., Ishii, H., Sato, K., Koshida, R., Ozaki, Y., Sata, M., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0598 · Cited by 47 · see citing works
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
Nicholls, S. J., Ray, K. K., Ballantyne, C. M., Beacham, L. A., Miller, D. L., Ruotolo, G., Nissen, S. E., & Riesmeyer, J. S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.008 · Cited by 44 · see citing works
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients
Thongtang, N., Lin, J., Schaefer, E. J., Lowe, R. S., Tomassini, J. E., Shah, A. K., & Tershakovec, A. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.001 · Cited by 41 · see citing works
One‐year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke‐free elderly with atrial fibrillation: evidence from a parallel group randomized trial
Tendolkar, I., Enajat, M., Zwiers, M. P., van Wingen, G. A., de Leeuw, F., van Kuilenburg, J. T., Bouwels, L., Pop, G., & Pop‐Purceleanu, M. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2688 · Cited by 41 · see citing works
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study
van Lennep, H. W. O. R., Liem, A. H., Dunselman, P. H. J. M., Dallinga‐Thie, G. M., Zwinderman, A. H., & Jukema, J. W. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273273 · Cited by 40 · see citing works
Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)
Devine, P. J., Turco, M. A., & Taylor, A. J. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6020-8 · Cited by 40 · see citing works
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe
Taylor, A. J., Villines, T. C., & Stanek, E. J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs105 · Cited by 40 · see citing works
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Xia, P., Tang, M., Liu, F., Shu, M., & Wu, X. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502 · Cited by 40 · see citing works
Self-citation
Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Lioudaki, E., Ganotakis, E. S., & Mikhailidis, D. P. (2010) · Current Vascular Pharmacology · doi:10.2174/157016111793744760 · Cited by 39 · see citing works
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
Stanifer, J. W., Charytan, D. M., White, J. A., Lokhnygina, Y. V., Cannon, C. P., Roe, M. T., & Blazing, M. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090957 · Cited by 39 · see citing works
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
Foody, J. M., Toth, P. P., Sajjan, S., Ramey, D. R., Neff, D., Tershakovec, A. M., Tunceli, K., Hu, H. X., & Tomassini, J. E. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s49840 · Cited by 38 · see citing works
The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation
Dağlı, N., Yavuzkır, M., & Karaca, I. (2007) · Inflammation · doi:10.1007/s10753-007-9041-3 · Cited by 37 · see citing works
Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36 · see citing works
Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery
Kouvelos, G. N., Arnaoutoglou, E. M., Matsagkas, M. I., Kostara, C. E., Gartzonika, C., Bairaktari, E. T., & Milionis, H. J. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412445506 · Cited by 35 · see citing works
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Zinellu, A., Sotgia, S., Mangoni, A., Sanna, M., Satta, A., & Carru, C. (2015) · NMCD. Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.11.004 · Cited by 34 · see citing works
Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study
Turk, T. R., Voropaeva, E., Kohnle, M., Nürnberger, J., Philipp, T., Kribben, A., Heemann, U. W., & Witzke, O. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm620 · Cited by 33 · see citing works
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)
Brunner, G., Yang, E. Y., Kumar, A., Sun, W., Virani, S. S., Negi, S., Murray, T. O., Lin, P. H., Hoogeveen, R. C., Chen, C., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.034 · Cited by 30 · see citing works
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER
Yamaguchi, J., Kawada‐Watanabe, E., Koyanagi, R., Arashi, H., Sekiguchi, H., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endo, Y., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.036 · Cited by 30 · see citing works
Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease
West, A. M., Anderson, J. D., Epstein, F. H., Meyer, C. H., Wang, H., Hagspiel, K. D., Berr, S. S., Harthun, N. L., WELTMAN, A. L., DiMaria, J. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.034 · Cited by 28 · see citing works
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
Le, N., Tomassini, J. E., Tershakovec, A. M., Neff, D., & Wilson, P. W. F. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001675 · Cited by 28 · see citing works
Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome
Liu, Z., Hao, H., Yin, C., Chu, Y., Li, J., & Xu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15078 · Cited by 28 · see citing works
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease
Wang, J., Ai, X.-B., Wang, F., Zou, Y., Li, L., & Yi, X. (2017) · International Angiology · doi:10.23736/s0392-9590.17.03818-4 · Cited by 28 · see citing works
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease
Okada, K., Iwahashi, N., Endo, T., Himeno, H., Fukui, K., Kobayashi, S., Shimizu, M., Iwasawa, Y., Morita, Y., Wada, A., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.07.036 · Cited by 27 · see citing works
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial
Tsujita, K., Yamanaga, K., Komura, N., Sakamoto, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Oka, H., Nakao, K., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.025 · Cited by 27 · see citing works
Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment
van Kuilenburg, J. T., Lappegård, K. T., Sexton, J., Plesiewicz, I., Lap, P., Bouwels, L., Sprong, T., Mollnes, T. E., Verheugt, F. W. A., van Heerde, W. L., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.05.003 · Cited by 26 · see citing works
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Davis, H. R., Murgolo, N., & Graziano, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmx080011 · Cited by 26 · see citing works
Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients
Suzuki, H., Watanabe, Y., Kumagai, H., & Shuto, H. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944713513222 · Cited by 25 · see citing works
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
Oikawa, S., Yamashita, S., Nakaya, N., Sasaki, J., Kono, S., & for the Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.35626 · Cited by 25 · see citing works
Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long‐Term Follow‐Up After Acute Coronary Syndromes
Fanaroff, A. C., Roe, M. T., Clare, R. M., Lokhnygina, Y. V., Návar, A. M., Giugliano, R. P., Wiviott, S. D., Tershakovec, A. M., D, E. B. M., & Blazing, M. A. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005840 · Cited by 25 · see citing works
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction
Ren, Y., Zhu, H., Fan, Z., Gao, Y., & Tian, N. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5175 · Cited by 24 · see citing works
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study
Pauriah, M., Elder, D. H. J., Ogston, S. A., Noman, A., Majeed, A., Wyatt, J. C., Choy, A. M., MacDonald, T. M., Struthers, A. D., & Lang, C. C. (2014) · Heart · doi:10.1136/heartjnl-2013-304678 · Cited by 23 · see citing works
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia
Luo, P., Li, L., Wang, L. X., Zhu, H., Du, S., Wu, S.-Z., Han, Y., & Wang, G. G. (2014) · Genetics and Molecular Research · doi:10.4238/2014.april.3.10 · Cited by 23 · see citing works
Ezetimibe-Statin Combination Therapy: Efficacy and Safety as Compared With Statin Monotherapy
Nußbaumer-Streit, B., Glechner, A., Kaminski-Hartenthaler, A., Mahlknecht, P., & Gartlehner, G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0445 · Cited by 23 · see citing works
Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy
Zinellu, A., Sotgia, S., Loriga, G., Deiana, L., Satta, A. E., & Carru, C. (2012) · Amino Acids · doi:10.1007/s00726-012-1223-0 · Cited by 22 · see citing works
Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease
Pytel, E., Bukowska, B., Koter−Michalak, M., Olszewska-Banaszczyk, M., Gorzelak‐Pabiś, P., & Broncel, M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.09.016 · Cited by 21 · see citing works
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Blazing, M. A., Giugliano, R. P., de Lemos, J. A., Cannon, C. P., Tonkin, A. M., Ballantyne, C. M., Lewis, B. S., Musliner, T. A., Tershakovec, A. M., Lokhnygina, Y. V., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.004 · Cited by 21 · see citing works
The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia
Santos, P. C. J. L., Alvarenga, A. M., Jannes, C. E., Krieger, J. E., Santos, R. D., & Pereira, A. C. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000089 · Cited by 19 · see citing works
Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease.
Luo, P., Wang, L., Zhu, H., Du, S., Wang, G., & Ding, S. (2016) · PubMed Central · doi:10.6515/acs20151013h · Cited by 18 · see citing works
Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
Sakamoto, K., Kawamura, M., Watanabe, T., Ashidate, K., Kohro, T., Tanaka, A., Mori, Y., Tagami, M., Hirano, T., Yamazaki, T., et al. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0508-4 · Cited by 18 · see citing works
Different Effects of Angiotensin Receptor Blockade on End-Organ Damage in Salt-Dependent and Salt-Independent Hypertension
Maitland, K. A., Bridges, L. E., Davis, W. P., Loscalzo, J., & Pointer, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.622316 · Cited by 17 · see citing works
Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality
Hayek, S., Canepa-Escaro, F., Sattar, A., Gamalski, S., Wells, K. E., Divine, G., Ahmedani, B. K., Lanfear, D. E., Pladevall, M., & Williams, L. K. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.002 · Cited by 17 · see citing works
Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
Teramoto, T., Abe, K., & Taneyama, T. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-163 · Cited by 16 · see citing works
A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk
Masiá, M., Bernal, E., Padilla, S., García, N., Escribano, J. C., Martínez, E., & Gutiérrez, F. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp250 · Cited by 16 · see citing works
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia
Bays, H. E., Sapre, A., Taggart, W. V., Ji, L., Capece, R., & Tershakovec, A. M. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802365094 · Cited by 16 · see citing works
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender
Japaridze, L., & Sadunishvili, M. (2017) · Kardiologia Polska · doi:10.5603/kp.a2017.0074 · Cited by 15 · see citing works
Effect of Low‐Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta‐Analyses, and Meta‐Regression Analyses of Randomized Trials
Thomopoulos, C., Skalis, G., Michalopoulou, H., Tsioufis, C. P., & Makris, T. (2015) · Clinical Cardiology · doi:10.1002/clc.22441 · Cited by 14 · see citing works
The Efficacy and Safety of Ezetimibe for Treatment of Dyslipidemia After Heart Transplantation
Crespo‐Leiro, M. G., Paniagua, M. J., Marzoa, R., Grille, Z., Naya, C., Flores, X. M., Rodríguez, J. A., Mosquera, V. X., Franco‐Gutiérrez, R., & Castro-Beiras, A. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.09.007 · Cited by 14 · see citing works
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Ono, T., Oka, H., et al. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.12.011 · Cited by 14 · see citing works
Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
Patel (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1371w · Cited by 14 · see citing works
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years
Dujovne, C. A., Suresh, R., Sisk, C. M., Maccubbin, D., Strony, J. T., & Veltri, E. P. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01798.x · Cited by 14 · see citing works
Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial
Tsujita, K., Yamanaga, K., Komura, N., Sakamoto, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Oka, H., Nakao, K., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316655465 · Cited by 14 · see citing works
Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study
Briguori, C., Quintavalle, C., D’Alessio, F., Donahue, M. E., Roscigno, G., Micco, F. D., Focaccio, A., Visconti, G., Vecchio, L. D., Madonna, R., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.087 · Cited by 14 · see citing works
Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients
Zinellu, A., Sotgia, S., Sotgiu, E., Assaretti, S., Baralla, A., Mangoni, A. A., Satta, A. E., & Carru, C. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.06.011 · Cited by 14 · see citing works
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience
Méte, M., Wilson, C., Lee, E. T., Silverman, A., Russell, M., Stylianou, M. P., Umans, J. G., Wang, W., Howard, W. J., Ratner, R. E., et al. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.04.001 · Cited by 13 · see citing works
Safety of the Combination of Intensive Cholesterol-Lowering Therapy with Oral Anticoagulation Medication in Elderly Patients with Atrial Fibrillation: A Randomized, Double-Blind, Placebo-Controlled Study
Enajat, M., Teerenstra, S., van Kuilenburg, J. T., van Sorge-Greve, A. H. N., Albers-Akkers, M. T. H., Verheugt, F. W. A., & Pop, G. A. M. (2009) · Drugs & Aging · doi:10.2165/10558450-000000000-00000 · Cited by 13 · see citing works
Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina
Arimura, T., Miura, S., Ike, A., Sugihara, M., Iwata, A., Nishikawa, H., Kawamura, A., & Saku, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.03.002 · Cited by 13 · see citing works
Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient‐important outcomes
Fei, Y., Guyatt, G. H., Alexander, P. E., Dib, R. E., Siemieniuk, R. A. C., Vandvik, P. O., Nunnally, M., Gomaa, H. A., Morgan, R. L., Agarwal, A., et al. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12663 · Cited by 13 · see citing works
LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy
Zinellu, A., Sotgia, S., Pisanu, E., Loriga, G., Deiana, L., Satta, A. E., & Carru, C. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.05.006 · Cited by 12 · see citing works
Randomized trial of atenolol versus losartan in children and young adults with Marfan syndrome
Lacro, R. V., Dietz, H. C., Sleeper, L. A., Yetman, A. T., Bradley, T. J., Colan, S. D., Pearson, G. D., Tierney, E. S. S., Levine, J. C., Atz, A. M., et al. (2014) · Ghent University Academic Bibliography (Ghent University) · Cited by 12 · see citing works
Rationale and design of a randomized trial of automated hovering for post–myocardial infarction patients: The HeartStrong program
Troxel, A. B., Asch, D. A., Mehta, S. J., Norton, L. A., Taylor, D., Calderón, T. A., Lim, R., Zhu, J., Kolansky, D. M., Drachman, B. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.006 · Cited by 12 · see citing works
Treatment With Ezetimibe in Kidney Transplant Recipients With Uncontrolled Dyslipidemia
López, V., Gutiérrez, C., Gutiérrez, E. M., Sola, E., Cabello, M., Burgos, D., & Molina, M. G. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.09.046 · Cited by 11 · see citing works
Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study
Russell, M., Silverman, A., Fleg, J. L., Lee, E. T., Méte, M., Weir, M. R., Wilson, C., Yeh, F., Howard, B. V., & Howard, W. J. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.07.007 · Cited by 11 · see citing works
Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study—Observational Study
Zhao, X.-Q., Phan, B. A. P., Davis, J., Isquith, D. A., Dowdy, A. A., Boltz, S., Neradilek, M. B., Monick, E. A., Brockenbrough, A., Frechette, E. E. H. S., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.013 · Cited by 11 · see citing works
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease
Zinellu, A., Sotgia, S., Mangoni, A. A., Sotgiu, E., Ena, S., Satta, A. E., & Carru, C. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.07.025 · Cited by 11 · see citing works
The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy
Madonna, R., Renna, F. V., Lanuti, P., Perfetti, M., Marchisio, M., Briguori, C., Condorelli, G., Manzoli, L., & Caterina, R. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172800 · Cited by 11 · see citing works
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003201 · Cited by 11 · see citing works
Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study
Hiro, T., Hirayama, A., Ueda, Y., Komatsu, S., Matsuoka, H., Takayama, T., Ishihara, M., Hayashi, T., Saito, S., & Kodama, K. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.02.026 · Cited by 10 · see citing works
Genetic Variants in Haem Oxygenase-1 and Endothelial Nitric Oxide Synthase Influence the Extent and Evolution of Coronary Artery Atherosclerosis
Král, A., Kovárník, T., Kralik, L., Skalická, H., Horák, J., Mintz, G. S., Uhrová, J., Milan Sonka, A., Wahle, A., Downe, R., et al. (2011) · Folia Biologica · doi:10.14712/fb2011057050182 · Cited by 10 · see citing works
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)
Kawada‐Watanabe, E., Ogawa, H., Koyanagi, R., Arashi, H., Yamaguchi, J., Matsui, K., & Hagiwara, N. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.05.002 · Cited by 9 · see citing works
Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia: a Randomized Control Trial
Kinouchi, K., Ichihara, A., Bokuda, K., Morimoto, S., & Itoh, H. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14860 · Cited by 8 · see citing works
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients
Strony, J. T., Hoffman, R., Hanson, M. E., & Veltri, E. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.008 · Cited by 8 · see citing works
Ezetimibe Effect on Bone Mineral Density and Markers of Bone Formation and Resorption
Sertbaş, Y., Ersoy, U., Ayter, M., Tırtıl, F. G., & Kuçükkaya, B. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181c9af4b · Cited by 8 · see citing works
Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study
Strony, J. T., Yang, B., Hanson, M. E., & Veltri, E. P. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802426581 · Cited by 7 · see citing works
BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS
Giugliano, R. P., Cannon, C. P., Blazing, M. A., White, J. A., Murphy, S. A., Tershakovec, A. M., Musliner, T., Califf, R. M., & D, E. B. M. (2015) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(15)60004-3 · Cited by 7 · see citing works
The Effect of Adding Ezetimibe to Rosuvastatin on Renal Function in Patients Undergoing Elective Vascular Surgery
Kouvelos, G. N., Arnaoutoglou, E. M., Milionis, H. J., Raikou, V. D., Papa, N. K., & Matsagkas, M. I. (2014) · Angiology · doi:10.1177/0003319713519492 · Cited by 7 · see citing works
Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease — Sub-analysis of PRECISE-IVUS trial
Fujisue, K., Nagamatsu, S., Shimomura, H., Yamashita, T., Nakao, K., Nakamura, S., Ishihara, M., Matsui, K., Yamamoto, N., Koide, S., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.04.051 · Cited by 7 · see citing works
4P-1212 The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression
Kastelein, J. J. P., Sager, P. T., de Groot, E., & Veltri, E. P. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)91468-1 · Cited by 6 · see citing works
A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE)
Steg, P. G., Verdier, J.-C., Carré, F., Darné, B. M., Ducardonnet, A., Jullien, G., Farnier, M., Giral, P., & Haiat, R. (2008) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2008.10.008 · Cited by 6 · see citing works
Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.
Suzuki, H., Inoue, T., Watanabe, Y., Kikuta, T., Sato, T., & Tsuda, M. (2010) · PubMed · Cited by 6 · see citing works
The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study
Jackowska, P., Pytel, E., Koter−Michalak, M., Olszewska-Banaszczyk, M., Legęza, A., & Broncel, M. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/34791 · Cited by 6 · see citing works
Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus
Lastra, O. L. V., Méndez‐Flores, S., Cruz-Domínguez, M. P., Medina, G., Aranda, E. C., & Jara, L. J. (2016) · Lupus · doi:10.1177/0961203316631631 · Cited by 5 · see citing works
Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial
Briguori, C., Madonna, R., Zimarino, M., Calabrò, P., Quintavalle, C., Salomone, M., Condorelli, G., & Caterina, R. D. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6672-3 · Cited by 5 · see citing works
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale
Inazawa, T., Sakamoto, K., Kohro, T., Iijima, R., Kitazawa, T., Hirano, T., Kawamura, M., Tagami, M., Tanaka, A., Mori, Y., et al. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-142 · Cited by 4 · see citing works
Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR
West, A. M., Anderson, J. D., Meyer, C. H., Epstein, F. H., Hagspiel, K. D., Berr, S. S., Harthun, N. L., DiMaria, J. M., Hunter, J. R., Christopher, J. M., et al. (2010) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-12-s1-p130 · Cited by 3 · see citing works
RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN THE IMPROVE-IT TRIAL
Bohula, E. A., White, J. A., Blazing, M. A., Giugliano, R. P., Musliner, T., Tershakovec, A. M., McCagg, A., Bhatt, D. L., Cannon, C. P., Califf, R. M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(15)60003-1 · Cited by 3 · see citing works
Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial
Nicholls, S. J., Ray, K. K., Ballantyne, C. M., Beacham, L. A., Miller, D. L., Ruotolo, G., & Riesmeyer, J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.017 · Cited by 3 · see citing works
LONG-TERM EFFECT OF EZETIMIBE-STATIN COMBINATION THERAPY ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING IN PATIENTS WITH CORONARY ARTERY DISEASE; FOCUS ON CHOLESTEROL ABSORPTION AND SYNTHESIS
Okada, K., Fukui, K., Himeno, H., Endo, T., Shimizu, M., KOBAYASHI, S., Shigemasa, T., Morita, Y., Wada, A., Shimizu, T., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(11)60524-x · Cited by 2 · see citing works
THE MECHANISM OF LONG-TERM LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING EFFECT OF EZETIMIBE-PLUS-STATIN COMBINATION THERAPY IN CORONARY ARTERY DISEASE PATIENTS; COMPARED WITH DOUBLE-DOSE STATIN THERAPY
Okada, K., Kimura, K., Iwahashi, N., Endo, T., Himeno, H., Shimizu, M., Wada, A., Wada, A., Uchino, K., & Umemura, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(12)61542-3 · Cited by 2 · see citing works
COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Japaridze, L., Sadunishvili, M., & Megreladze, I. (2016) · PubMed · Cited by 2 · see citing works
Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study
Ferrières, J., Dallongeville, J., Rossignol, M., Bénichou, J., Jaime, J., Getsios, D., Hernandez, L. G., Abenhaim, L., & Grimaldi‐Bensouda, L. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.015 · Cited by 2 · see citing works
P857The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins
Katoh, A., Hattori, Y., Yoshikwa, N., Niiyama, H., Harada, H., Kai, H., & Ikeda, H. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx501.p857 · Cited by 2 · see citing works
THE DIFFERENT EFFECTS OF STATIN AND EZETIMIBE COMBINATION ON CORONARY ATHEROMA PLAQUE IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS: SUB-ANALYSIS OF PRECISE-IVUS TRIAL
Fujisue, K., Nagamatsu, S., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Sakamoto, K., Nakao, K., Nakamura, S., Ishihara, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)32322-2 · Cited by 2 · see citing works
A reversal of Glagov's hypothesis; a preliminary demonstration by cardiac magnetic resonance
Kodali, S., Doyle, M., Grant, S. B., Neff, D., Williams, R. B., Yamrozik, J., Rayarao, G., Angheloiu, G. O., Rathi, V. K., & Biederman, R. W. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-s1-p178 · Cited by 1 · see citing works
Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy
West, A. M., Pesch, A. J., Mehta, N. S., Anderson, J. D., Epstein, F. H., Meyer, C. H., Hagspiel, K. D., Berr, S. S., Harthun, N. L., Hunter, J. R., et al. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-s1-p382 · Cited by 1 · see citing works
TCT-384 Effect of Ezetimibe in addition to Statin Therapy in statin naïve STEMI patients assessed by Optical Coherence Tomography and Intravascular Ultrasound with iMap (The OCTIVUS trial)
Hougaard, M., Hansen, H. S., Junker, A., Thayssen, P., Antonsen, L., Maehara, A., & Jensen, L. O. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.432 · Cited by 1 · see citing works
857 LOW-DOSE PRAVASTATIN PLUS EZETIMIBE VERUS STANDARD-DOSE PRAVASTATIN: THE EFFECT ON THE CAROTID ATHEROSCLEROSIS OF PATIENTS WITH HYPERCHOLESTEROLEMIA
Sawavama, Y. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70858-3 · Cited by 1 · see citing works
Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis
Kodali, S., Doyle, M., Grant, S. B., Neff, D., Williams, R. B., Yamrozik, J., Rayarao, G., Angheloiu, G. O., Rathi, V. K., & Biederman, R. W. (2012) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-14-s1-o43 · Cited by 1 · see citing works
MS409 AN IMPROVEMENT OF ENDOTHELIAL DYSFUNCTION MARKERS IN CHRONIC KIDNEY DISEASE SIMVASTATIN/EZETIMIBE COMBINED THERAPY
Carru, C., Loriga, G., Farre, G., Zinellu, A., Sotgia, S., Scanu, B., Pisanu, E., Sanna, M., Deiana, L., & Satta, A. E. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)70910-7 · Cited by 1 · see citing works
ASSESSMENT OF ATRIAL LATE POTENTIALS IN PATIENTS WITH HYPERCHOLESTEREMIA, TO INVESTIGATE THE PREVENTIVE EFFECT OF PITAVASTATIN ON ATRIAL FIBRILLATION (ALPINA STUDY)
Okuyama, Y., Kuramoto, Y., Kawasaki, M., Iwasaki, Y., Tanaka, K., Furukawa, Y., Morita, T., Yamada, T., Ueda, H., Komuro, I., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(12)60688-3 · Cited by 1 · see citing works
Abstract: 1050 THE SANDS TRIAL: THE EFFECT OF STATINS WITH VERSUS WITHOUT EZETIMIBE ON CAROTID ATHEROSCLEROSIS IN TYPE 2 DIABETES
Fleg, J. L., Meta, M., Howard, B. V., Roman, M., & Howard, W. H. R. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)70170-9 · Cited by 1 · see citing works
Exercise capacity predictors in hypertrophic obstructive cardiomyopathy patients assessed by multi-modality imaging
Austin, B. A., Popović, Z., Kwon, D. H., Thamilarasan, M., Boonyasirinant, T., Flamm, S. D., Lever, H. M., & Desai, M. Y. (2010) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-12-s1-p192 · Cited by 1 · see citing works
Reply
Tsujita, K., Sugiyama, S., Shimomura, H., Yamanaga, K., Kaikita, K., Hokimoto, S., & Ogawa, H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.053 · Cited by 1 · see citing works
739 EZETIMIBE PRESERVES RENAL FUNCTION IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH FLUVASTATIN
Kinouchi, K., Ichihara, A., Bokuda, K., Morimoto, S., & Itoh, H. (2012) · Journal of Hypertension · doi:10.1097/01.hjh.0000420710.53898.26 · Cited by 1 · see citing works
Abstract 13849: Impact of Statin-Ezetimibe Combination on Coronary Atheroma Progression/Regression in Patients With and Without Prior Statin Therapy - Subanalysis of PRECISE-IVUS Trial
Tsujita, K., Yamanaga, K., Sugiyama, S., Shimomura, H., Yamashita, T., Sakamoto, K., Nakao, K., Nakamura, S., Ishihara, M., Matsui, K., et al. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.13849 · Cited by 1 · see citing works
DUAL LIPID-LOWERING WITH EZETIMIBE/STATIN AS A PROMISING ANTI-ATHEROSCLEROTIC STRATEGY
Tsujita, K., Yamanaga, K., Komura, N., Shimomura, H., Ishihara, M., Kaikita, K., Hokimoto, S., & Ogawa, H. (2016) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(16)32133-7 · Cited by 1 · see citing works
LONG TERM SIGNIFICANCE OF HEART FAILURE COMPLICATING ACUTE MYOCARDIAL INFARCTION IN 11,185 PATIENTS FROM THE IMPROVED REDUCTION OF OUTCOMES: VYTORIN EFFICACY INTERNATIONAL TRIAL (IMPROVE-IT)
Silverman, M. G., Cannon, C. P., Blazing, M. A., Mach, F., Zhou, J., Tershakovec, A. M., & Giugliano, R. P. (2016) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(16)30485-5 · Cited by 1 · see citing works
Utilidad del tratamiento con atorvastatina 40 mg más ezetimiba 10 mg frente a atorvastatina 80 mg en la reducción de los niveles de colesterol LDL en pacientes con ictus isquémico o ataque isquémico transitorio
Portilla, E. P., Viadero-Cervera, R., García, M. Á. R., Larrosa, D., Acha, O., Robledo, F. N., & Durán, A. O. (2016) · Revista de Neurología · doi:10.33588/rn.6205.2015353 · Cited by 1 · see citing works
Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: Results of the efectl trial
Oikawa, S., Yamashita, S., Nakaya, N., Sasaki, J., Kono, S., & G. EFECTL Study Investigators (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.217 · Cited by 1 · see citing works
Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction:a nationwide cohort study
Sehested, T. S. G., Fosbøl, E. L., Hansen, P. W., Charlot, M. G., Torp-Pedersen, C. T., & Gislason, G. (2016) · VBN Forskningsportal (Aalborg Universitet) · doi:10.1093/eurheartj/ehw434 · Cited by 1 · see citing works
IMPACT OF HIGH SENSITIVITY C REACTIVE PROTEIN LEVELON CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME PATIENTS WITH DYSLIPIDEMIA UNDERGOING CONTEMPORARY LIPID LOWERING THERAPY
Watanabe, E., Ogawa, R., Yamaguchi, J., Sekiguchi, H., Ogiso, M., Arashi, H., Ogawa, H., & Hagiwara, N. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)30594-1 · Cited by 1 · see citing works
P1119The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER
Kanbayashi, K., Yamaguchi, J., Fujii, S., Kawada‐Watanabe, E., Arashi, H., Sekiguchi, H., Ogawa, H., Hagiwara, N., & HIJ PROPER Investigators (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx502.p1119 · Cited by 1 · see citing works
Abstract 17307: Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT Trial
Qamar, A., Giugliano, R. P., Blazing, M. A., Park, J. G., Murphy, S. A., Cannon, C. P., D, E. B. M., & Morrow, D. A. (2017) · Circulation · Cited by 1 · see citing works
Abstract 13048: The Impact of Statin-Ezetimibe Combination Therapy in Patients With Decreased Cholesterol Absorption Ability
Yamanaga, K., Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Komura, N., Sakamoto, K., Oka, H., Nakao, K., et al. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.13048 · Cited by 1 · see citing works
Abstract 17275: The Natural History of Patients Post-Acute Coronary Syndrome Based on Heart Failure Status - An Analysis of the IMPROVE-IT Trial
Ambrosy, A. P., Cerbin, L., Clare, R. M., Lokhnygina, Y. V., Tershakovec, A. M., Roe, M. T., & Blazing, M. A. (2017) · Circulation · Cited by 1 · see citing works
MORTALITY REDUCTION IN PATIENTS TREATED WITH LONG-TERM INTENSIVE LIPID THERAPY: 20-YEAR FOLLOW-UP OF THE FAMILIAR ATHEROSCLEROSIS TREATMENT STUDY- OBSERVATIONAL STUDY
Zhao, X. Q., Davis, J., Isquith, D. A., Dowdy, A. A., Boltz, S., Neradilek, M. B., & Brown, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(14)61287-0 · Cited by 1 · see citing works

Flagged first, then by citations

4 of the 202 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

[9]9. Markers indicating obesity (e.g. adiponectin), inflammation (high-sensitive C-reactive protein), oxidative stress, early-staged kidney diseases (microalbuminuria), 6/12/24 months after randomi- sation Notes Date of registration: 03/01/2010 Recruitment status: Terminated Location: Japan Contact information: Katsunori Ikewaki; katsunorike@ndmc.ac.jp Expected completion date: unknown Contacted trialists to ask about status and anticipated completion date, but no response. JPRN-UMIN000002964 Methods Parallel Randomized, open label study Participants Inclusion criteria: JPRN-UMIN000011745 Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[14]14. markers indicating inflammation (e.g. high-sensitive C-reactive protein); 6. markers indicating oxidative stress; 7. markers indicating chronic renal diseases (urine albumin / liver fatty acid-binding protein); 8. blood/urine urate levels; 9. Body weight/waist circumference; 10.blood pressures. Notes Date of registration: 14/09/2013 Recruitment status: Completed Location: Japan Contact information: Katsunori Ikewaki (katsunorike@ndmc.ac.jp) Expected completion date: unknown Contacted trialists to ask about status and anticipated completion date, but no response. JPRN-UMIN000011745 (Continued) Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Secondary: 1. change in normalised total atheroma volume (TAV) in non-culprit lesions (Time Frame: 12 months after index CAG);
[30]30. LDL cholesterol concentration > 100 mg/dL (2.59 mmol/L). Exclusion Criteria: (in adults with dialysis-dependent CKD) NCT03543774 Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 1. exp ezetimibe/ 2. (ezetimibe or ezetimib).tw.
[35]35. exp animals/ not humans.sh. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews 21. 19 not 20 22. 10 and 21 Embase Ovid 1. exp ezetimibe/ 2. (ezetimibe or ezetimib).tw.

Sorted by citations

Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease
Naylor, R., Rantner, B., Ancetti, S., de Borst, G. J., Carlo, M. D., Halliday, A. W., Kakkos, S. K., Markus, H. S., McCabe, D. J. H., Sillesen, H. H., et al. (2022) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2022.04.011 · Cited by 944 · see citing works
Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G. P. R., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 477 · see citing works
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274 · see citing works
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
Khan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069116 · Cited by 151 · see citing works
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 136 · see citing works
JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease
Nakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1041 · Cited by 130 · see citing works
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
Cicero, A. F. G., Fogacci, F., Hernández, A. V., & Banach, M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003121 · Cited by 107 · see citing works
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 95 · see citing works
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 84 · see citing works
Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments
Silveira, É. A., Vaseghi, G., Santos, A. S. E. A. D. C., Kliemann, N., Masoudkabir, F., Noll, M. A., Mohammadifard, N., Sarrafzadegan, N., & de Oliveira, C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239042 · Cited by 78 · see citing works
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
O’Malley, P. G., Arnold, M. J., Kelley, C., Spacek, L., Buelt, A., Natarajan, S., Donahue, M., Vagichev, E., Ballard‐Hernandez, J., Logan, A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4648 · Cited by 70 · see citing works
Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
Thongtang, N., Sukmawan, R., Llanes, E. J. B., & Lee, Z.-V. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101819 · Cited by 61 · see citing works
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58 · see citing works
Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data
Lewek, J., Niedziela, J. T., Desperak, P., Dyrbuś, K., Osadnik, T., Jankowski, P., Witkowski, A., Bielecka-Dabrowa, A. M., Dudek, D., Gierlotka, M. J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030414 · Cited by 57 · see citing works
Brown Algae Potential as a Functional Food against Hypercholesterolemia: Review
André, R., Pacheco, R., Bourbon, M., & Serralheiro, M. L. (2021) · Foods · doi:10.3390/foods10020234 · Cited by 54 · see citing works
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 63 · see citing works
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 47 · see citing works
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 48 · see citing works
Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies
Wang, Y., Zhan, S., Du, H., Li, J., Khan, S. U., Aertgeerts, B., Guyatt, G. H., Hao, Q., Bekkering, G. E., Li, L., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000134 · Cited by 44 · see citing works
Self-citation
Etiology and Management of Dyslipidemia in Patients With Cancer
de Jesus, M., Mohammed, T. J., Singh, M., Tiu, J. G., & Kim, A. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.892335 · Cited by 32 · see citing works
Lipid-Modifying Therapies and Stroke Prevention
Hackam, D. G., & Hegele, R. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01197-4 · Cited by 30 · see citing works
The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events
Maierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 31 · see citing works
The effects of tocotrienol supplementation on lipid profile: A meta-analysis of randomized controlled trials
Zuo, S., Wang, G., Han, Q., Xiao, H., Santos, H. O., Rodriguez, D. A., Khani, V., & Tang, J. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102450 · Cited by 29 · see citing works
Statin Use Associates With Risk of Type 2 Diabetes via Epigenetic Patterns at ABCG1
Liu, Y.-W., Shen, Y., Guo, T., Parnell, L. D., Westerman, K. E., Smith, C. E., Ordovás, J. M., & Lai, C. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00622 · Cited by 25 · see citing works
2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke
Chen, P.-S., Lee, M., Tang, S., Huang, P., Yeh, H., Hou, C. J., Hsieh, C., Lee, J., Jeng, J., & Li, Y. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.03.001 · Cited by 23 · see citing works
Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis
Soleimani, H., Mousavi, A., Shojaei, S., Tavakoli, K., Salabat, D., Rad, F. F., Askari, M. K., Nelson, J. R., Ruzieh, M., & Hosseini, K. (2024) · Clinical Cardiology · doi:10.1002/clc.24334 · Cited by 20 · see citing works
Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective
Liang, Z., Chen, Q., Yang, F., Yan, X., Zhang, X., Xue, C., Fang, F., & Zhao, Q. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07079-6 · Cited by 22 · see citing works
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20 · see citing works
Drugs in secondary stroke prevention
Tremonti, C., & Thieben, M. J. (2021) · Australian Prescriber · doi:10.18773/austprescr.2021.018 · Cited by 20 · see citing works
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19 · see citing works
Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings
Muntner, P., Ghazi, L., Jones, J., Dhalwani, N. N., Poudel, B., Wen, Y. R., Chen, L., Wang, Z., Bittner, V., Kalich, B. A., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02868-z · Cited by 17 · see citing works
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care
Dugré, N., Lindblad, A. J., Perry, D. M., Allan, G., Braschi, E., Falk, J., Froentjes, L. S., Garrison, S. R., Kirkwood, J., Korownyk, C., et al. (2023) · Canadian Family Physician Médecin de famille canadien · doi:10.46747/cfp.6910701 · Cited by 15 · see citing works
Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study
Jun, J. E., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae081 · Cited by 17 · see citing works
Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
Bays, H. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100003 · Cited by 19 · see citing works
Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bhagavathula, A. S., Aldhaleei, W. A., Matrooshi, N. O. A., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00951-1 · Cited by 15 · see citing works
Ezetimibe Induces Paraptosis through Niemann–Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells
Yin, Y., Wu, C., Zhou, Y., Zhang, M., Mai, S., Chen, M., & Wang, H. (2023) · Genes · doi:10.3390/genes15010004 · Cited by 15 · see citing works
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13 · see citing works
Synthesis and Modeling of Ezetimibe Analogues
Salgado, M. M., Manchado, A., Nieto, C. T., David Diez, A., & Garrido, N. M. (2021) · Molecules · doi:10.3390/molecules26113107 · Cited by 13 · see citing works
Pharmacological interventions for asymptomatic carotid stenosis
Clezar, C. N., Flumignan, C. D. Q., Cassola, N., Nakano, L. C. U., Trevisani, V. F. M., & Flumignan, R. L. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013573.pub2 · Cited by 13 · see citing works
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Lee, J., & Lee, S. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.243 · Cited by 13 · see citing works
Association of apolipoprotein levels with peripheral arterial disease: a meta-analysis of literature studies
Forte, F., Calcaterra, I. L., Lupoli, R., Orsini, R. C., Chiurazzi, M., Tripaldella, M., Iannuzzo, G., & Minno, M. N. D. D. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa029 · Cited by 13 · see citing works
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13 · see citing works
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
Heinrich, N. S., Pedersen, R. P., Vestergaard, M. B., Lindberg, U., Andersen, U. B., Haddock, B., Hansen, T. W., Fornoni, A., Larsson, H. B. W., & Rossing, P. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15146 · Cited by 9 · see citing works
Recommending Drug Combinations Using Reinforcement Learning targeting Genes/proteins associated with Heterozygous Familial Hypercholesterolemia: A comprehensive Systematic Review and Net-work Meta-analysisPreprint
Kiaei, A. A., Boush, M., Abadijou, S., Momeni, S., Safaei, D., Bahadori, R., Salari, N., & Mohammadi, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2379891/v1 · Cited by 9 · see citing works
PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration
Eloso, J., Awad, A., Zhao, X., Cunningham, F. E., Zhang, R., Dong, D., Kelley, C., Glassman, P. A., & Aspinall, S. L. (2023) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2023.100035 · Cited by 8 · see citing works
Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification
Marquina, C., Morton, J. I., Zomer, E., Talic, S., Lybrand, S., Thomson, D., Liew, D., & Ademi, Z. (2022) · Value in Health · doi:10.1016/j.jval.2022.11.013 · Cited by 8 · see citing works
Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis
Cai, R., Chang, C., Zhong, X., & Su, Q. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0004 · Cited by 8 · see citing works
Pearls & Oy-sters: Managing Cholesterol in a Patient With Statin Intolerance Due to Anti-HMG-CoA Reductase–Associated Myopathy
Villa, E., Naves, R. F., Bezares, K., Cobeña, K., Villarroel, A. C., & Carlos Guevara, O. (2022) · Neurology · doi:10.1212/wnl.0000000000201315 · Cited by 8 · see citing works
Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe
Bays, H. E. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.8 · Cited by 8 · see citing works
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7 · see citing works
Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event
Engebretsen, I., Bugge, C., Støvring, H., Husebye, E., Sverre, E., Dammen, T., Halvorsen, S., & Munkhaugen, J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117550 · Cited by 8 · see citing works
Effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in managing hypercholesterolemia post-statin-associated immune-mediated necrotizing myopathy: report of five cases and literature review
Yerolatsite, M., Torounidou, N., Gerolymatou, N., Panteli, A., Koletsos, N., Karakosta, M., Zarkavelis, G., & Voulgari, P. V. (2025) · Rheumatology International · doi:10.1007/s00296-025-05860-0 · Cited by 7 · see citing works
Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis
Wu, X.-D., Ye, X.-Y., Liu, X.-Y., Lin, Y., Lin, X. Y., Li, Y., Ye, B.-H., & Sun, J.-C. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2389470 · Cited by 7 · see citing works
Self-citation
Ezetimibe in the management of homozygous familial hypercholesterolaemia
Mansfield, B. S., Dello-Iacono, A., & Raal, F. J. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.003 · Cited by 6 · see citing works
Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics
González‐Iglesias, E., Ochoa, D., Navares‐Gómez, M., Zubiaur, P., Aldama, M., de la Torre, T., Ríos-Rodríguez, M. D. L., Soria‐Chacartegui, P., Rodríguez‐Lopez, A., Abad‐Santos, F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414059 · Cited by 6 · see citing works
Advances in the management of statin myopathy
Gallo, A., Perregaux, J., & Bruckert, É. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000595 · Cited by 6 · see citing works
Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential
Priani, S. E., Chaerunisaa, A. Y., Wilar, G., & Sopyan, I. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s550340 · Cited by 10 · see citing works
▼Inclisiran: more hope less hype
(2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2022.000009 · Cited by 5 · see citing works
Are We Using Ezetimibe As Much As We Should?
Manolis, A. S., Manolis, T. A., Mikhailidis, D. P., & Manolis, A. S. (2024) · Biomarker Insights · doi:10.1177/11772719241257410 · Cited by 5 · see citing works
Pharmacological interventions for asymptomatic carotid stenosis
Clezar, C. N., Cassola, N., Flumignan, C. D. Q., Nakano, L. C. U., Trevisani, V. F. M., & Flumignan, R. L. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013573 · Cited by 5 · see citing works
Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021).
Arrieta, F., Pedro-Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G., Becerra, A., Navarro, J., Pérez, J. C., Petrecca, R., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.05.002 · Cited by 5 · see citing works
Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kwon, R. J., Cho, Y. H., Park, E. J., Lee, Y., Lee, S. R., Choi, J. I., Lee, S. Y., & Son, S. M. (2023) · Medicina · doi:10.3390/medicina59111980 · Cited by 5 · see citing works
Unraveling Potential Sex‐Specific Effects of Cardiovascular Medications on Longevity Using Mendelian Randomization
Kwok, M. K., & Schooling, C. M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030943 · Cited by 4 · see citing works
Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
Rodríguez‐Saldaña, J., Padilla, F., Cardona-Muñóz, E. G., Romero‐Antonio, Y., Arguedas-Núñez, M. M., Sander-Padilla, J. G., Muñoz, A. M., Lugo‐Sánchez, L. A., Rodríguez-Vázquez, I. C., & González‐Canudas, J. (2022) · Cardiology Research and Practice · doi:10.1155/2022/9464733 · Cited by 4 · see citing works
Maximizing Benefits and Minimizing Adverse Effects of Statins
Schade, D. S., Blankenship, J. C., & Eaton, R. P. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.07.029 · Cited by 4 · see citing works
Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study
Xiao, W., Li, Y., Zhuang, Z., Song, Z., Wang, W., Huang, N., Dong, X. Y., Jia, J., Liu, Z., Zhao, Y., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02133-w · Cited by 4 · see citing works
Optimal Prescribing of Statins to Reduce Cardiovascular Disease
Schade, D. S., Duro, T., & Eaton, R. P. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.06.030 · Cited by 4 · see citing works
Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 3 · see citing works
Hypolipidemic Therapy in Patients with Chronic Liver Diseases: What Should a Gastroenterologist Know
Sandler, Y. G., & Vinnitskaya, E. V. (2021) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2021-17-28-36-45 · Cited by 3 · see citing works
Cholesterol transport in blood, lipoproteins, and cholesterol metabolism
Auley, M. T. M., & Morgan, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00025-0 · Cited by 3 · see citing works
Small interfering RNA effect on lipoprotein(a): a systematic review
Almaadawy, O., Hesn, M., Elsalamony, Y. A., Abobakr, O. A., Elshimy, A., Abualkhair, K. A., Negm, M. M., Shaban, A. Y., Bene-Alhasan, Y. O., Annie, F., et al. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00635-1 · Cited by 4 · see citing works
Blood viscosity – The unifying cardiovascular disease risk biomarker
Finlayson, E. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104904 · Cited by 2 · see citing works
Are current dietary guidelines relevant to subjects on cholesterol-lowering drugs?
Salter, A. M. (2019) · Proceedings of The Nutrition Society · doi:10.1017/s0029665119000685 · Cited by 2 · see citing works
Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols
Dayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2 · see citing works
Intensive Medical Management to Prevent Large and Small Artery Atherothrombotic Stroke
Lee, M., Ovbiagele, B. I., & Saver, J. L. (2021) · JAMA · doi:10.1001/jama.2021.9917 · Cited by 2 · see citing works
Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences
Олеговна, К. Е., Никитина, А. В., & Валерьевич, С. И. (2024) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2024.264 · Cited by 1 · see citing works
Ezetimibe plus moderate-intensity statin versus high-intensity statin
BMJ Publishing Group Ltd (2023) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000008 · Cited by 1 · see citing works
Acute Achilles tendon rupture: Skip the surgery?
Tassone, P. T. (2023) · The Journal of Family Practice · doi:10.12788/jfp.0604 · Cited by 1 · see citing works
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
Reddy, V. (2023) · The Journal of Family Practice · doi:10.12788/jfp.0610 · Cited by 1 · see citing works
Lipidstoffwechselstörungen
Schirmer, B., & Schuler, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_11 · Cited by 1 · see citing works
Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study
Roh, J. W., Park, M.-H., Son, J.-W., Bae, S., & the HM-ROS-OS-2102 Study Investigator Group (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01482-3 · Cited by 1 · see citing works
Identification of the Organic Volatile Impurities in Ezitamibe using GC-HS Technique
Rapeti, D., Narayanarao, K. M. V., Shyamala, P., & Krishna, R. M. (2021) · Asian Journal of Chemistry · doi:10.14233/ajchem.2021.23071 · Cited by 1 · see citing works
Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021)
Arrieta, F., Pedro-botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G., Becerra, A., Navarro, J., Pérez, J. C., Petrecca, R., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.01.005 · Cited by 1 · see citing works
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease
Wang, L., & Tang, X. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3369226 · Cited by 1 · see citing works
Retracted
Metabolic syndrome and cancer risk
Majumder, A., & Acharya, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00052-9 · Cited by 1 · see citing works
Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes
Lopez-Ayala, P., Glarner, N., & Mueller, C. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2305917 · Cited by 1 · see citing works
Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based StudyPreprint
Chou, O. H. I., Li, L., Chung, C. T., Lü, L., Lee, Q., Pui, H. H. H., Leung, B. K. H., Chang, C., Liu, T., Wai, A. K. C., et al. (2023) · medRxiv · doi:10.1101/2023.09.23.23296003 · Cited by 1 · see citing works
Can ezetimibe help to prevent cardiovascular disease events and mortality?
Burch, J., & Gruenebaum, D. D. (2019) · Cochrane Clinical Answers · doi:10.1002/cca.2486
Cholesterol verlagen: fire and forget
Krukerink, M., Honkoop, P., & Bruggink, S. C. (2019) · Huisarts en Wetenschap · doi:10.1007/s12445-019-0264-y
Prevention of Stroke by Lowering Blood Cholesterol Concentrations
Paciaroni, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316286234.017
Herramientas para el control de la dislipemia en el paciente con DM2: dieta, ejercicio y fármacos
Pardo, D. E. (2021) · doi:10.52102/control_dislipemia/art-4
Sekundärprävention
Köhrmann, M., Kraft, P., Reiff, T., & Ringleb, P. A. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-23431-6.00012-6
Lipidstoffwechselstörungen
Schirmer, B., & Schuler, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_11
Neurology
Hoffmann, M. W., Cywes, R., Childers, A. M., Kossoff, M. M., Kossoff, E. H., Perlmutter, D., Phillips, M. C. L., Edes, G., Berger, A., Stanton, A. A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00006-1
Tolvaptan Kullanan Polikistik Böbrek Hastasinda Statin Eklenmesine Bağlı Karaciğer Fonksiyon Bozukluğunun Yönetimi
Demiray, A., Koyuncu, S., Ozan, R., CİVAN, M., & Kocyigit, I. D. (2023) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1362557
Lipidstoffwechselstörungen
Schirmer, B., & Schuler, J. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_11
MÉTODOS DE TRATAMENTO INTEGRADOS NO CUIDADOS DAS DOENÇAS CARDIOVASCULARES: A IMPORTÂNCIA DAS ESTRATÉGIAS DE PREVENÇÃO PRIMÁRIA E SECUNDÁRIA
Gurian, A. D. O. V., Teles, A. E. L., Bozi, A., Mantovi, C. K., Moreira, F. G., da Silva, F. M. A., Gonçalves, L. B., Silveira, T. L. D. S., da Silva, T. B., & Lista, P. V. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p121
Exploring the impact of insurance switching on the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers
Hendy, L. E., Spees, L. P., Tak, C. R., Carpenter, D. M., Thomas, K. C., & Roberts, M. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.003

The Role of Ezetimibe in the Treatment of Cardiovascular Disease
Agarwala, A., Kajani, Z., Miedema, M. D., & Virani, S. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0560-y · Cited by 13 · see citing works
Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36 · see citing works
The role of ezetimibe in the prevention of cardiovascular disease: Where do we stand after ARBITER 6-HALTS
Howard, W. J. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.05.002 · Cited by 9 · see citing works
RESEARCH ARTICLE Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battaggia, R., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2016)
Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Badarin, F. J. A., Kullo, I. J., Kopecky, S. L., & Thomas, R. J. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60545-4 · Cited by 26 · see citing works

Authors: Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X.
Affiliations: Army Medical University (CN)
ORCID: Liu, Fang
Wu, Xiaojiao
Venue: Cochrane Database of Systematic Reviews
Publisher: Wiley
Published: 2018-11-19
Volume: 2018
Issue: 11
Pages: CD012502-CD012502
ISSN: 1361-6137 (ISSN-L)
1465-1858
DOI: 10.1002/14651858.cd012502.pub2
PMC: PMC6516816
OpenAlex: W2778116940
Semantic Scholar: 24392a10a2db231bd0830e952fca00b38d0309f5
Cited by: 109
References: 202
Citations by year: 2026: 8 · 2025: 6 · 2024: 14 · 2023: 26 · 2022: 23 · 2021: 11 · 2020: 15 · 2019: 4 · 2018: 1 · 2017: 1
FWCI: 1.72
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: ezetimibe, cardiovascular disease prevention, all-cause mortality, major adverse cardiovascular events, cholesterol absorption inhibition, statin intolerance, lipid-modifying drugs, LDL cholesterol, IMPROVE-IT trial, statin-sparing therapy, drug safety, adverse events, hypercholesterolemia, cardiovascular risk reduction, cardiovascular risk stratification
MeSH terms: Ezetimibe, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Cause of Death, Cholesterol, Drug Therapy, Combination, Humans, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Fenofibrate, Triglycerides, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks